% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • ries123 ries123 Sep 3, 2014 8:17 AM Flag

    PR Hot from the wires

    Insmed Announces Multiple Clinical and Scientific Presentations at European Respiratory Society's International Congress 2014
    Introduces INS-1009 (Treprostinil) for the Treatment of Pulmonary Arterial Hypertension

    BRIDGEWATER, NJ -- (Marketwired) -- 09/03/14 -- Insmed Incorporated (NASDAQ: INSM) announces that the Company's novel inhalation technologies for the treatment of orphan pulmonary diseases will be highlighted in a variety of clinical and scientific presentations at the European Respiratory Society's (ERS) International Congress 2014, taking place September 6-10, 2014 at the Internationales Congress Center München in Munich, Germany.

    There will be several presentations regarding the Company's lead product ARIKAYCE™, or liposomal amikacin for inhalation delivered by an investigational eFlow® Nebulizer System (PARI Pharma GmbH), for the treatment of both nontuberculous mycobacteria lung infections (NTM) and Pseudomonas aeruginosa in cystic fibrosis patients. In addition, the Company will present several posters regarding INS-1009 (treprostinil), the Company's novel inhalation formulation of a proven prostacyclin for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

    Insmed has applied its product design, drug development and sustained-release formulation expertise to advance INS-1009 with the goal of addressing current limitations of inhaled prostacyclin therapies in the treatment of PAH. INS-1009 is expected to be delivered once-daily via inhalation. It is designed to provide consistent, effective drug levels and may also reduce the acute systemic effects of current treatment options.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think I suggested some time ago to keep an eye Dr. Perkins at Insmed. Although a relatively small population, inhaled treprostinil shows how quickly he can apply liposomal technology with proven medicaments for other indications.

      • 3 Replies to biowatchdog
      • Replay this post.
        I think I suggested some time ago to keep an eye Dr. Perkins at Insmed. Although a relatively small population, inhaled treprostinil shows how quickly he can apply liposomal technology with proven medicaments for other indications.

        Sentiment: Strong Buy

      • Here is what biowatchdog posted on April 10th. Go down to the bottom


        The good doctor says they must explain the control arm results? Is there a benefit attributable to liposomes?

        Why do you think we are developing a liposomal delivery for antibiotics? We know…
        1) Liposomes stimulate the mononuclear phagocyte system (MPS). MPS plays a major role in the aspecific host defense against infection;
        2) Liposomes are very similar to natural membranes and can be administered safely. They degrade naturally;
        3) Liposomes are unable to leave general circulation on their own and are preferentially taken up by the MPS cells. So they stimulate the natural body defender, as well as deliver a desired agent;
        4) Liposomes size and surface can be constructed to reduce the uptake by MPS and prolong circulation;
        5) Liposomal delivery can be inhaled or intravenous;
        6) Liposomes can encapsulate any number of agents;
        7) Intravenous delivery of liposomes uptake by MPS occurs mainly in the Liver and spleen;
        8) Liposomal delivery of agents has been seen effective in malaria, histoplasmosis, cryptococcosis, leukopenia, and others.

        Regarding #8 and liposomes in general, one only needs to read Dr. Perkins’ bio to understand where Insmed is heading. I cannot provide the url here, but just google Walter Perkins and who will find an article where he mentions new work he is doing at Insmed

      • I wonder if presently in Europe or if we do eventually get an FDA Approval for either CF or NTM, if this will validate to the point of allowing us/them to bypass full Phase Clinical Trials for other Liposomal attached Medications?

    • "We believe INS-1009 and its sustained-release inhaled formulation of prostacyclin may prolong duration of effect and provide greater consistency in the reduction of pulmonary arterial pressure over time. As a result, this may reduce the acute impact of drug treatment on heart rate, blood pressure and the severity and/or frequency of cough. Moreover, current inhaled prostacyclin therapies must be dosed four to nine times per day. Reducing dose frequency to once-daily would ease patient burden and may positively impact compliance," stated Walter Perkins, Ph.D., Chief Technology Officer of Insmed.

      "We are particularly pleased to have the depth of data presented on ARIKAYCE in both NTM and Pseudomonas aeruginosa in cystic fibrosis patients as we move forward with plans to submit for licensure with the European Medicines Agency in both indications. In addition, the introduction of INS-1009 is testament to our innovative research and development team and underscores our commitment to new treatments for orphan lung diseases. We believe we can address the current limitations of inhaled prostacyclin therapies in PAH with our proven design, development and formulation expertise," noted Will Lewis, President and Chief Executive Officer of Insmed.

      Sentiment: Strong Buy

    • This is GREAT news!!

      Sentiment: Strong Buy

14.07+0.03(+0.21%)2:54 PMEDT